Andrew Wolanski

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia LoRusso, Jing Li, Angelika M. Burger et al. · Clinical Cancer Research · 2016 · 109 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

“Entering a clinical trial: Is it right for you?”

Brianna Hoffner, Susan Bauer‐Wu, Suzanne Hitchcock‐Bryan et al. · Cancer · 2011 · 49 citations · Full text

Nursing, Communication, Oncology +17

Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors

Joseph P. Eder, Elisabeth I. Heath, Leonard J. Appleman et al. · Journal of Clinical Oncology · 2007 · 46 citations

Medicine, Oncology, Pharmacology +17

Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors

Geoffrey I. Shapiro, T. Khanh, Sara M. Tolaney et al. · Cancer Research · 2017 · 12 citations

Medicine, Oncology, Pharmacology +15

Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

T. Khanh, Nicole G. Chau, Andrew Wolanski et al. · Cancer Research · 2018 · 12 citations

Medicine, Oncology, Pharmacology +17